Melissa Barker-Haliski

Dr. Melissa Barker-Haliski

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2015 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
MBMelissa Barker-Haliski
Melissa Barker-Haliski
HWH. Steve White
H. Steve White
Epilepsy is broadly characterized by aberrant neuronal excitability. Glutamate is the predominant excitatory neurotransmitter in the adult mammalian brain; thus, much of past epilepsy research has attempted to understand the role of glutamate in seizures and epilepsy. Seizures induce elevations in extracellular glutamate, which then contribute to excitotoxic damage. Chronic seizures can alter neuronal and glial expression of glutamate receptors and uptake transporters, further contributing to epileptogenesis. Evidence points to a shared glutamate pathology for epilepsy and other central nervous system (CNS) disorders, including depression, which is often a comorbidity of epilepsy. Therapies that target glutamatergic neurotransmission are available, but many have met with difficulty because of untoward adverse effects. Better understanding of this system has generated novel therapeutic targets that directly and indirectly modulate glutamatergic signaling. Thus, future efforts to manage the epileptic patient with glutamatergic-centric treatments now hold greater potential.

26 December 2018 in Epilepsia
Verified
Journal Article
Open access
PDF file
PPPabitra Hriday Patra
Pabitra Hriday Patra
MBMelissa Barker-Haliski
Melissa Barker-Haliski
HWH. Steve White
H. Steve White
BWBenjamin J. Whalley
Benjamin J. Whalley
SGSarah Glyn
Sarah Glyn
AMAlister James McNeish
Alister James McNeish
Summary: Objective: Epilepsy is a progressive neurological disease characterized by recurrent seizures and behavioral comorbidities. We investigated the antiseizure effect of cannabidiol (CBD) in a battery of acute seizure models. Additionally, we defined the disease‐modifying potential of chronic oral administration ofCBDon associated comorbidities in the reduced intensity status epilepticus–spontaneous recurrent seizures (RISE‐SRS) model of temporal lobe epilepsy (TLE).Methods: We evaluated the acute antiseizure effect ofCBDin the maximal electroshock seizure, 6‐Hz psychomotor seizure, and pentylenetetrazol acute seizure tests, as well as the corneal kindling model of chronic seizures in mice following intraperitoneal administration. Median effective or behavioral toxic dose was determined in both mice and rats. Next, we tested an intravenous preparation ofCBD(10 mg/kg single dose) in a rat model of pilocarpine‐induced status epilepticus. We defined the effect of chronicCBDadministration (200 mg/kg orally) on spontaneous seizures, motor control, gait, and memory function in the ratRISE‐SRSmodel ofTLE.Results: CBD was effective in a battery of acute seizure models in both mice and rats following intraperitoneal administration. In the pilocarpine‐induced status epilepticus rat model,CBDattenuated maximum seizure severity following intravenous administration, further demonstratingCBD's acute antiseizure efficacy in this rat model. We established that oralCBDattenuated the time‐dependent increase in seizure burden and improvedTLE‐associated motor comorbidities of epileptic rats in theRISE‐SRSmodel without affecting gait. Chronic administration ofCBDafter the onset ofSRSameliorated reference memory and working memory errors of epileptic animals in a spatial learning and memory task.Significance: The present study illustrates thatCBDis a well‐tolerated and effective antiseizure agent and illustrates a potential disease‐modifying effect ofCBDon reducing both seizure burden and associated comorbidities well after the onset of symptomatic seizures in a model ofTLE.

4 July 2017 in Epilepsia
Verified
Journal Article
Open access
PDF file
MBMelissa Barker-Haliski
Melissa Barker-Haliski
WLWolfgang Löscher
Wolfgang Löscher
HWH. Steve White
H. Steve White
AGAristea Galanopoulou
Aristea Galanopoulou
Summary: Animal models have provided a wealth of information on mechanisms of epileptogenesis and comorbidogenesis, and have significantly advanced our ability to investigate the potential of new therapies. Processes implicating brain inflammation have been increasingly observed in epilepsy research. Herein we discuss the progress on animal models of epilepsy and comorbidities that inform us on the potential role of inflammation in epileptogenesis and comorbidity pathogenesis in rodent models of West syndrome and the Theiler's murine encephalomyelitis virus (TMEV) mouse model of viral encephalitis–induced epilepsy. Rat models of infantile spasms were generated in rat pups after right intracerebral injections of proinflammatory compounds (lipopolysaccharides with or without doxorubicin, or cytokines) and were longitudinally monitored for epileptic spasms and neurodevelopmental and cognitive deficits. Anti‐inflammatory treatments were tested after the onset of spasms. The TMEV mouse model was induced with intracerebral administration of TMEV and prospective monitoring for handling‐induced seizures or seizure susceptibility, as well as long‐term evaluations of behavioral comorbidities of epilepsy. Inflammatory processes are evident in both models and are implicated in the pathogenesis of the observed seizures and comorbidities. A common feature of these models, based on the data so far available, is their pharmacoresistant profile. The presented data support the role of inflammatory pathways in epileptogenesis and comorbidities in two distinct epilepsy models. Pharmacoresistance is a common feature of both inflammation‐based models. Utilization of these models may facilitate the identification of age‐specific, syndrome‐ or etiology‐specific therapies for the epilepsies and attendant comorbidities, including the drug‐resistant forms.

1 March 2016 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
JLJaycie L. Loewen
Jaycie L. Loewen
MBMelissa Barker-Haliski
Melissa Barker-Haliski
EDE. Jill Dahle
E. Jill Dahle
HWH. Steve White
H. Steve White
KWKaren S. Wilcox
Karen S. Wilcox
It is estimated that 30%–40% of epilepsy patients are refractory to therapy and animal models are useful for the identification of more efficacious therapeutic agents. Various well-characterized syndrome-specific models are needed to assess their relevance to human seizure disorders and their validity for testing potential therapies. The corneal kindled mouse model of temporal lobe epilepsy (TLE) allows for the rapid screening of investigational compounds, but there is a lack of information as to the specific inflammatory pathology in this model. Similarly, the Theiler murine encephalomyelitis virus (TMEV) model of TLE may prove to be useful for screening, but quantitative assessment of hippocampal pathology is also lacking. We used immunohistochemistry to characterize and quantitate acute neuronal injury and inflammatory features in dorsal CA1 and dentate gyrus regions and in the directly overlying posterior parietal cortex at 2 time points in each of these TLE models. Corneal kindled mice were observed to have astrogliosis, but not microgliosis or neuron cell death. In contrast, TMEV-injected mice had astrogliosis, microgliosis, neuron death, and astrocyte and microglial proliferation. Our results suggest that these 2 animal models might be appropriate for evaluation of distinct therapies for TLE.

27 August 2019 in Neuropharmacology
Verified
Journal Article
Closed access
MBMelissa Barker-Haliski
Melissa Barker-Haliski
HWH. Steve White
H. Steve White

16 March 2017 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
MBMelissa Barker-Haliski
Melissa Barker-Haliski
KJKristina Johnson
Kristina Johnson
PBPeggy Billingsley
Peggy Billingsley
JHJennifer Huff
Jennifer Huff
LHLaura J. Handy
Laura J. Handy
KWKaren S. Wilcox
Karen S. Wilcox